| Year |
Citation |
Score |
| 2024 |
Korell F, Olson ML, Salas-Benito D, Leick MB, Larson RC, Bouffard A, Silva H, Gasparetto A, Berger TR, Kann MC, Mergen M, Kienka T, Wehrli M, Haradhvala NJ, Bailey SR, ... Letai A, et al. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics. Science Translational Medicine. 16: eadk7640. PMID 38838132 DOI: 10.1126/scitranslmed.adk7640 |
0.363 |
|
| 2023 |
Jovanović B, Temko D, Stevens LE, Seehawer M, Fassl A, Murphy K, Anand J, Garza K, Gulvady A, Qiu X, Harper NW, Daniels VW, Xiao-Yun H, Ge JY, Alečković M, ... ... Letai AG, et al. Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell Reports. 42: 113564. PMID 38100350 DOI: 10.1016/j.celrep.2023.113564 |
0.482 |
|
| 2023 |
Parvin S, Aryal A, Yin S, Fell GG, Davids MS, Wu CJ, Letai A. Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia. Blood Advances. PMID 37428863 DOI: 10.1182/bloodadvances.2022008207 |
0.353 |
|
| 2023 |
Lecky E, Mukherji A, German R, Antonellis G, Lin JR, Yorsz M, McQueeney KE, Ryan J, Ng K, Sicinska E, Sorger PK, Letai A, Bhola PD. Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells. Science Advances. 9: eadg4128. PMID 37352344 DOI: 10.1126/sciadv.adg4128 |
0.409 |
|
| 2023 |
Potter DS, Du R, Bohl SR, Chow KH, Ligon KL, Bueno R, Letai A. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nature Communications. 14: 2897. PMID 37210412 DOI: 10.1038/s41467-023-38552-z |
0.329 |
|
| 2023 |
Pourzia AL, Olson ML, Bailey SR, Boroughs AC, Aryal A, Ryan J, Maus MV, Letai A. Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. Cell Death & Disease. 14: 267. PMID 37055388 DOI: 10.1038/s41419-023-05727-x |
0.401 |
|
| 2022 |
Winter JM, Fresenius HL, Cunningham CN, Wei P, Keys HR, Berg JA, Bott AJ, Yadav T, Ryan JA, Sirohi D, Tripp SR, Barta P, Agarwal N, Letai A, Sabatini DM, et al. Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. Elife. 11. PMID 36409067 DOI: 10.7554/eLife.82860 |
0.352 |
|
| 2022 |
Pan R, Ryan J, Pan D, Wucherpfennig KW, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. PMID 35447071 DOI: 10.1016/j.cell.2022.03.030 |
0.354 |
|
| 2022 |
Bodaar K, Yamagata N, Barthe A, Landrigan J, Chonghaile TN, Burns M, Stevenson KE, Devidas M, Loh ML, Hunger SP, Wood B, Silverman LB, Teachey DT, Meijerink JP, Letai A, et al. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. PMID 35411095 DOI: 10.1038/s41375-022-01558-5 |
0.356 |
|
| 2021 |
Skourti E, Letai A. In Conversation with Tony Letai. The Febs Journal. 288: 6087-6094. PMID 34719878 DOI: 10.1111/febs.16229 |
0.329 |
|
| 2021 |
Alcon C, Gómez Tejeda Zañudo J, Albert R, Wagle N, Scaltriti M, Letai A, Samitier J, Montero J. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells. 10. PMID 34359829 DOI: 10.3390/cells10071659 |
0.314 |
|
| 2021 |
Potter DS, Du R, Bhola P, Bueno R, Letai A. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. Cell Death & Disease. 12: 741. PMID 34315868 DOI: 10.1038/s41419-021-04029-4 |
0.367 |
|
| 2021 |
Daniels VW, Zoeller JJ, van Gastel N, McQueeney KE, Parvin S, Potter DS, Fell GG, Ferreira VG, Yilma B, Gupta R, Spetz J, Bhola PD, Endress JE, Harris IS, Carrilho E, ... ... Letai A, et al. Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. Science Signaling. 14. PMID 34103421 DOI: 10.1126/scisignal.abc7405 |
0.339 |
|
| 2021 |
Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, Clare Beytagh M, Xuan L, Feldser DM, Hemann MT, Zamudio J, Dimitrova N, Letai A, Jacks T. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34074758 DOI: 10.1073/pnas.2019740118 |
0.355 |
|
| 2021 |
Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, ... ... Letai A, et al. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48. PMID 33997789 DOI: 10.1038/s43018-020-00135-y |
0.55 |
|
| 2021 |
Rys RN, Wever CM, Geoffrion D, Goncalves C, Ghassemian A, Brailovski E, Ryan J, Stoica L, Hébert J, Petrogiannis-Haliotis T, Dmitrienko S, Frenkiel S, Staiger A, Ott G, Steidl C, ... ... Letai A, et al. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. Cancers. 13. PMID 33670870 DOI: 10.3390/cancers13051002 |
0.383 |
|
| 2021 |
Dowling CM, Hollinshead KER, Di Grande A, Pritchard J, Zhang H, Dillon ET, Haley K, Papadopoulos E, Mehta AK, Bleach R, Lindner AU, Mooney B, Düssmann H, O'Connor D, Prehn JHM, ... ... Letai AG, et al. Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Science Advances. 7. PMID 33523897 DOI: 10.1126/sciadv.abc4897 |
0.303 |
|
| 2021 |
Dimitrova V, Sotudeh N, Montanaro A, Yun H, Potdar SV, Van Scoyk A, Bhatt S, Anand P, Kokkalis A, Kloeber JA, Frede J, Waldschmidt JM, Letai AG, Weinstock DM, Lohr JG, et al. Maturity State and MCL-1 Dependence Predetermines Response to NOTCH1 Inhibition in T-ALL Blood. 138: 3484-3484. DOI: 10.1182/blood-2021-153829 |
0.336 |
|
| 2020 |
Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint AJ, Bohl SR, Kim AS, Mehta AK, ... ... Letai A, et al. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. PMID 33217342 DOI: 10.1016/j.ccell.2020.10.010 |
0.329 |
|
| 2020 |
Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, Trujillo-Alonso V, Teater MR, van Besien H, Gibbs-Curtis D, Ueno H, Parvin S, Letai A, Mathew S, Singh A, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Advances. 4: 5226-5231. PMID 33104794 DOI: 10.1182/bloodadvances.2020002580 |
0.408 |
|
| 2020 |
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. The New England Journal of Medicine. 383: 617-629. PMID 32786187 DOI: 10.1056/Nejmoa2012971 |
0.305 |
|
| 2020 |
Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL, Stein EM, Tallman MS, Sen F, Famulare CA, Cusan M, Huang CH, Chen CW, Zou L, Cordner KB, ... ... Letai A, et al. Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition. Cancer Discovery. PMID 32606137 DOI: 10.1158/2159-8290.Cd-19-1469 |
0.441 |
|
| 2020 |
Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, Ni J, Chipashvili O, Hagan T, Pioso MS, McQueeney K, Ng K, Aguirre AJ, Cleary JM, Cocozziello D, ... ... Letai A, et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Science Signaling. 13. PMID 32546544 DOI: 10.1126/Scisignal.Aay1451 |
0.38 |
|
| 2020 |
Adamia S, Bhatt S, Tai Y, Wen K, Nicholas CA, Pioso MS, Abiatari I, Letai AG, Anderson K. Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM) Blood. 136: 22-23. DOI: 10.1182/blood-2020-142596 |
0.306 |
|
| 2020 |
Parvin S, Aryal A, Davids MS, Letai AG. CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients Blood. 136: 13-14. DOI: 10.1182/blood-2020-141642 |
0.35 |
|
| 2020 |
Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS. Abstract P3-11-06: Pre-clinical assessment of combined ABT-263/Navitoclax and ABT-414 or ABBV-321 treatment for EGFR-expressing TNBC Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-11-06 |
0.344 |
|
| 2020 |
Fernandez E, Mai W, Bayley N, Tse C, Liau L, Cloughesy T, Letai A, Nathanson D. CBIO-25. INTEGRATED MOLECULAR AND BH3 PROFILING OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA Neuro-Oncology. 22: ii21-ii21. DOI: 10.1093/neuonc/noaa215.085 |
0.367 |
|
| 2019 |
Garcia JS, Bhatt S, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, ... Letai A, et al. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. American Journal of Hematology. PMID 31804723 DOI: 10.1002/Ajh.25692 |
0.416 |
|
| 2019 |
Montero J, Gstalder C, Kim DJ, Sadowicz D, Miles W, Manos M, Cidado JR, Paul Secrist J, Tron AE, Flaherty K, Stephen Hodi F, Yoon CH, Letai A, Fisher DE, Haq R. Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications. 10: 5157. PMID 31727958 DOI: 10.1038/S41467-019-12477-Y |
0.462 |
|
| 2019 |
Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, ... ... Letai AG, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. PMID 31543463 DOI: 10.1016/J.Ccell.2019.08.005 |
0.435 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Letai A, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243 |
0.497 |
|
| 2019 |
Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. The Journal of Clinical Investigation. PMID 31437130 DOI: 10.1172/Jci128571 |
0.408 |
|
| 2019 |
Ortiz MV, Ahmed S, Burns M, Henssen AG, Hollmann TJ, MacArthur I, Gunasekera S, Gaewsky L, Bradwin G, Ryan J, Letai A, He Y, Naranjo A, Chi YY, LaQuaglia M, et al. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. Jci Insight. 4. PMID 31391345 DOI: 10.1172/Jci.Insight.127098 |
0.373 |
|
| 2019 |
Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, ... ... Letai A, et al. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications. 10: 3485. PMID 31375684 DOI: 10.1038/S41467-019-11371-X |
0.48 |
|
| 2019 |
Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, ... ... Letai A, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death & Disease. 10: 571. PMID 31358732 DOI: 10.1038/S41419-019-1801-0 |
0.528 |
|
| 2019 |
Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death and Differentiation. PMID 31332296 DOI: 10.1038/S41418-019-0391-9 |
0.49 |
|
| 2019 |
Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, ... ... Letai A, et al. Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs. Blood. PMID 31043423 DOI: 10.1182/Blood.2019000789 |
0.359 |
|
| 2019 |
Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, Hahn WC. MCL1 and DEDD promote urothelial carcinoma progression. Molecular Cancer Research : McR. PMID 30777879 DOI: 10.1158/1541-7786.Mcr-18-0963 |
0.357 |
|
| 2019 |
Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nature Reviews. Molecular Cell Biology. PMID 30655609 DOI: 10.1038/S41580-018-0089-8 |
0.459 |
|
| 2019 |
Liu VM, Guièze R, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez AZ, Ten Hacken E, Thompson PA, Iorgulescu JB, Li S, Davids MS, Brown JR, Lako A, Ciantra ZB, Lawlor MA, ... ... Letai AG, et al. MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers Blood. 134: 1284-1284. DOI: 10.1182/Blood-2019-131336 |
0.357 |
|
| 2019 |
Dimitrova V, Yun H, Potdar S, Scoyk ANV, Bhatt S, Anand P, Nair MS, Kloeber JA, Kokkalis A, Frede J, Waldschmidt JM, Letai AG, Weinstock DM, Aster JC, Lohr JG, et al. Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL Blood. 134: 3948-3948. DOI: 10.1182/Blood-2019-131148 |
0.321 |
|
| 2019 |
Bhatt S, Pioso M, Olesinski EA, Yilma B, Buon L, Adamia S, Zhu H, Ryan J, Wang Y, Erick M, Halilovic E, Weinstock DM, Garcia JS, Letai A. Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia Blood. 134: 2551-2551. DOI: 10.1182/Blood-2019-131101 |
0.368 |
|
| 2019 |
Yin S, Parvin S, Ten Hacken E, Valentin R, Joyal H, Rassenti LZ, Ghia EM, Kipps TJ, Neuberg DS, Wang L, Davids MS, Carrasco RD, Letai AG, Wu CJ. Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL Blood. 134: 4281-4281. DOI: 10.1182/Blood-2019-127293 |
0.432 |
|
| 2019 |
Pratz KW, DiNardo CD, Arellano ML, Letai AG, Thirman M, Pullarkat VA, Roboz GJ, Becker PS, Hong W, Jiang Q, Hayslip J, Potluri J, Pollyea DA. Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies Blood. 134: 264-264. DOI: 10.1182/Blood-2019-127251 |
0.313 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... ... Letai A, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14 |
0.485 |
|
| 2019 |
Dowling C, Dillion E, Hemann M, Cagney G, Letai A, Chonghaile TN. Abstract 5186: Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-5186 |
0.323 |
|
| 2019 |
Bhola PD, Ahmed E, Guerriero J, Sicinska E, Su E, Ni J, Lavrova E, Chipashvili O, Hagan T, Ng K, Aguirre A, Lorch J, George S, Demetri G, Zhao J, ... Letai A, et al. Abstract 4478: High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4478 |
0.329 |
|
| 2019 |
Bhatt S, Yilma B, Olesinski E, Zhu H, Murakami M, Murali VK, Adamia S, Weinstock DM, Garcia JS, Letai A. Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy Cancer Research. 79: 2990-2990. DOI: 10.1158/1538-7445.Sabcs18-2990 |
0.458 |
|
| 2019 |
Potter DS, Letai AG. Abstract 2496: Dynamic BH3 profiling identifies active combinations with conventional chemotherapy in non-small cell lung cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2496 |
0.364 |
|
| 2019 |
German R, Lavrova E, Hagan T, Chipashvili O, Sicinska E, Cleary J, Ng K, Letai A, Bhola P. Abstract 260: Identifying cancer drug sensitivity using live cell imaging dynamic BH3 profiling of solid tumor core biopsies Cancer Research. 79: 260-260. DOI: 10.1158/1538-7445.Am2019-260 |
0.457 |
|
| 2019 |
Fernandez E, Mai W, Bayley N, Liau L, Cloughesy T, Letai A, Nathanson D. CBMT-44. COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA Neuro-Oncology. 21: vi42-vi42. DOI: 10.1093/Neuonc/Noz175.166 |
0.473 |
|
| 2018 |
Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller A, Cidado J, Letai A, et al. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. PMID 30498064 DOI: 10.1182/Blood-2018-07-865527 |
0.503 |
|
| 2018 |
Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, ... ... Letai AG, et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. The Journal of Experimental Medicine. PMID 30404791 DOI: 10.1084/Jem.20180570 |
0.451 |
|
| 2018 |
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, ... Letai A, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. PMID 30361262 DOI: 10.1182/Blood-2018-08-868752 |
0.331 |
|
| 2018 |
Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B, Shipp MA. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. PMID 30322870 DOI: 10.1182/Blood-2018-08-872465 |
0.455 |
|
| 2018 |
Hacken ET, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, ... ... Letai A, et al. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. Jci Insight. 3. PMID 30282833 DOI: 10.1172/Jci.Insight.121438 |
0.49 |
|
| 2018 |
Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 132: 1007-1012. PMID 30037885 DOI: 10.1182/Blood-2018-03-828269 |
0.445 |
|
| 2018 |
Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, Andrews DW. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. Embo Reports. PMID 29987135 DOI: 10.15252/Embr.201745235 |
0.484 |
|
| 2018 |
Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, Fereshetian S, Krug K, Zhu H, Letai A, Carr SA, et al. PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. PMID 29954749 DOI: 10.1182/Blood-2018-05-850339 |
0.418 |
|
| 2018 |
Taylor Ripley R, Surman DR, Diggs LP, Trepel JB, Lee MJ, Ryan J, Davis JL, Steinberg SM, Hernandez JM, Hoang C, Kenney CM, Bond CD, Kunst TF, Letai A, Schrump DS. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. Bmc Gastroenterology. 18: 94. PMID 29933761 DOI: 10.1186/S12876-018-0823-X |
0.381 |
|
| 2018 |
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, ... ... Letai A, et al. Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10. PMID 29899021 DOI: 10.1126/Scitranslmed.Aaq1240 |
0.806 |
|
| 2018 |
Letai A. Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 36: 1991-1993. PMID 29787358 DOI: 10.1200/Jco.2018.78.2763 |
0.331 |
|
| 2018 |
Gutierrez-Martinez P, Hogdal L, Nagai M, Kruta M, Singh R, Sarosiek K, Nussenzweig A, Beerman I, Letai A, Rossi DJ. Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nature Cell Biology. PMID 29531308 DOI: 10.1038/S41556-018-0054-Y |
0.324 |
|
| 2018 |
Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, ... ... Letai A, et al. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery. PMID 29431698 DOI: 10.1158/2159-8290.Cd-17-1271 |
0.406 |
|
| 2018 |
Rezaei Araghi R, Bird GH, Ryan JA, Jenson JM, Godes M, Pritz JR, Grant RA, Letai A, Walensky LD, Keating AE. Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 29339518 DOI: 10.1073/Pnas.1712952115 |
0.413 |
|
| 2018 |
DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology. PMID 29339097 DOI: 10.1016/S1470-2045(18)30010-X |
0.372 |
|
| 2018 |
Guieze R, Liu VM, Rosebrock D, Jourdain A, Hernández-Sánchez M, Martinez Az, Jing S, Baranowski KJ, Thompson PA, Jin-Mi H, Cartun Z, Aygun O, Notarangelo G, Livitz D, Li S, ... ... Letai A, et al. Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies Blood. 132: 893-893. DOI: 10.1182/Blood-2018-99-118604 |
0.396 |
|
| 2018 |
Johnson NA, Wever CM, Geoffrion D, Artin G, Eugene B, Sesques P, Ryan JA, Stoica L, Hebert J, Petrogiannis-Haliotis T, Dmitrienko S, Saul F, Ott G, Staiger A, Steidl C, ... ... Letai A, et al. Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling Blood. 132: 4126-4126. DOI: 10.1182/Blood-2018-99-118225 |
0.506 |
|
| 2018 |
Garcia JS, Bhatt S, Fell G, Blonquist TM, Taw J, Iberri D, Letai A, Medeiros BC. Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia Blood. 132: 4058-4058. DOI: 10.1182/Blood-2018-99-117428 |
0.344 |
|
| 2018 |
Pollyea DA, Pratz KW, Jonas BA, Letai A, Pullarkat VA, Wei A, Konopleva MY, Recher C, Frankfurt O, Rizzieri D, Xu T, Dail M, Chyla B, Potluri J, DiNardo CD. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy Blood. 132: 285-285. DOI: 10.1182/Blood-2018-99-117179 |
0.357 |
|
| 2018 |
Bodaar K, Aries IM, Karim S, Chonghaile TN, Burns MA, Hinze L, Pfirrmann M, Degar J, Landrigan J, Balbach S, Peirs S, Menten B, Stevenson KE, Neuberg DS, Devidas M, ... ... Letai A, et al. PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL Blood. 132: 889-889. DOI: 10.1182/Blood-2018-99-113518 |
0.406 |
|
| 2018 |
DiNardo CD, Pratz K, Potluri J, Pullarkat V, Jonas BA, Wei AH, Becker PS, Frankfurt O, Xu T, Hong W, Chyla B, Pollyea DA, Letai A. Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 18: S201. DOI: 10.1016/J.Clml.2018.07.050 |
0.325 |
|
| 2017 |
Terai H, Kitajima S, Potter DS, Matsui Y, Gutierrez Quiceno L, Chen T, Kim TJ, Rusan M, Thai TC, Piccioni F, Donovan KA, Kwiatkowski N, Hinohara K, Wei G, Gray NS, ... ... Letai A, et al. ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors. Cancer Research. PMID 29259014 DOI: 10.1158/0008-5472.Can-17-1904 |
0.422 |
|
| 2017 |
Lagares D, Santos A, Grasberger PE, Liu F, Probst CK, Rahimi RA, Sakai N, Kuehl T, Ryan J, Bhola P, Montero J, Kapoor M, Baron M, Varelas X, Tschumperlin DJ, ... Letai A, et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Science Translational Medicine. 9. PMID 29237758 DOI: 10.1126/Scitranslmed.Aal3765 |
0.446 |
|
| 2017 |
Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Cancer Discovery. PMID 29146569 DOI: 10.1158/2159-8290.Cd-17-0797 |
0.494 |
|
| 2017 |
Saito Y, Mochizuki Y, Ogahara I, Watanabe T, Hogdal L, Takagi S, Sato K, Kaneko A, Kajita H, Uchida N, Fukami T, Shultz LD, Taniguchi S, Ohara O, Letai AG, et al. Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. Science Translational Medicine. 9. PMID 29070697 DOI: 10.1126/Scitranslmed.Aao1214 |
0.397 |
|
| 2017 |
Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, et al. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature Communications. 8: 1123. PMID 29066722 DOI: 10.1038/S41467-017-01079-1 |
0.436 |
|
| 2017 |
Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, ... ... Letai A, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine. PMID 29035366 DOI: 10.1038/Nm.4418 |
0.366 |
|
| 2017 |
Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology. PMID 28967922 DOI: 10.1038/Nchembio.2486 |
0.388 |
|
| 2017 |
Letai A. Functional precision cancer medicine—moving beyond pure genomics Nature Medicine. 23: 1028-1035. PMID 28886003 DOI: 10.1038/Nm.4389 |
0.341 |
|
| 2017 |
Jenson JM, Ryan JA, Grant RA, Letai A, Keating AE. Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. Elife. 6. PMID 28594323 DOI: 10.7554/Elife.25541 |
0.4 |
|
| 2017 |
Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, ... Letai A, et al. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 6. PMID 28561737 DOI: 10.7554/Elife.24523 |
0.455 |
|
| 2017 |
Price AM, Dai J, Bazot Q, Patel L, Nikitin PA, Djavadian R, Winter PS, Salinas CA, Barry AP, Wood KC, Johannsen EC, Letai A, Allday MJ, Luftig MA. Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife. 6. PMID 28425914 DOI: 10.7554/Elife.22509 |
0.414 |
|
| 2017 |
Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. PMID 28273064 DOI: 10.1038/Nature21409 |
0.301 |
|
| 2017 |
Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. PMID 28111464 DOI: 10.1038/leu.2017.32 |
0.401 |
|
| 2017 |
Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang H, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, ... Letai A, et al. Author response: Synergistic interactions with PI3K inhibition that induce apoptosis Elife. DOI: 10.7554/Elife.24523.023 |
0.368 |
|
| 2017 |
Price AM, Dai J, Bazot Q, Patel L, Nikitin PA, Djavadian R, Winter PS, Salinas CA, Barry AP, Wood KC, Johannsen EC, Letai A, Allday MJ, Luftig MA. Author response: Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection Elife. DOI: 10.7554/Elife.22509.036 |
0.341 |
|
| 2017 |
DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, Kantarjian HM, Pigneux A, Recher C, Seymour JF, Dunbar M, Xu T, Mabry M, Potluri J, Pratz K, ... Letai A, et al. Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Blood. 130: 2628-2628. DOI: 10.1182/Blood.V130.Suppl_1.2628.2628 |
0.331 |
|
| 2017 |
Aries I, Chonghaile TN, Karim S, Balbach S, Burns M, Pouliot G, Kristen S, Neuberg D, Devidas M, Mignon L, Hunger S, Winter S, Teachey D, Rabin K, Dunsmore K, ... ... Letai AG, et al. Abstract PR14: Polycomb repressive complex 2 inactivation induces primary chemotherapy resistance in T-ALL by upregulating the TRAP1 mitochondrial chaperone Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Pr14 |
0.471 |
|
| 2017 |
Letai AG. Abstract IA19: Directing blood cancer therapy with mitochondrial BH3 profiling Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Ia19 |
0.457 |
|
| 2017 |
Hacken Et, Wang L, Regis FF, Thomas M, Deng J, Baranowski K, Cartun Z, Buonamici S, Neuberg D, Letai A, Carrasco R, Wu CJ. Abstract 29: Characterization and treatment of a novel adoptive transfer model of Sf3b1mut/Atmdel chronic lymphocytic leukemia Clinical Cancer Research. 23: 29-29. DOI: 10.1158/1557-3265.Hemmal17-29 |
0.426 |
|
| 2017 |
Ortiz MV, Burns M, Eisenberg A, Ahmed S, Gaewsky L, Bradwin G, Cifani P, Henssen A, Macarthur I, LaQuaglia M, Letai A, Naranjo A, Gadd S, Chi Y, Dome J, et al. Abstract 708: Prohibitin is a prognostic marker of treatment failure and therapeutic target to block chemotherapy resistance in Wilms tumor Cancer Research. 77: 708-708. DOI: 10.1158/1538-7445.Am2017-708 |
0.408 |
|
| 2017 |
Dowling CM, Hemann M, Bradner J, Letai A, Chonghaile TN. Abstract 2326: A high-throughput screen identified cancer selective small molecules that kill independent of mitochondrial apoptosis Cancer Research. 77: 2326-2326. DOI: 10.1158/1538-7445.Am2017-2326 |
0.436 |
|
| 2017 |
Letai A. Apoptosis and Cancer Annual Review of Cancer Biology. 1: 275-294. DOI: 10.1146/ANNUREV-CANCERBIO-050216-121933 |
0.425 |
|
| 2017 |
Strasser A, Letai AG. Webinar | Deciphering cancer: Investigating cell death mechanisms Science. 358: 819-819. DOI: 10.1126/Science.358.6364.819-B |
0.502 |
|
| 2017 |
Brem E, Koch R, Clark R, Kupper T, Weinstock D, Letai A. BH3 Mimetics May Have Utility in T Cell Non-Hodgkin Lymphomas Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.07.202 |
0.316 |
|
| 2017 |
Zhang Q, Han L, Shi C, Jacamo R, Pan R, Chun John MM, Jeremy R, Kurtz S, Mu H, Ruvolo V, Ma H, Andreeff M, Mi Y, Tyner J, Leverson J, ... Letai A, et al. Upregulation of MCL-1 through MAPK Activation Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML Clinical Lymphoma Myeloma and Leukemia. 17: S285. DOI: 10.1016/J.Clml.2017.07.069 |
0.355 |
|
| 2016 |
Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, ... ... Letai A, et al. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. PMID 28017613 DOI: 10.1016/J.Ccell.2016.11.011 |
0.449 |
|
| 2016 |
Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SW, Gautier F, Juin PP. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Reports. 17: 3347-3358. PMID 28009301 DOI: 10.1016/J.Celrep.2016.11.064 |
0.471 |
|
| 2016 |
Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, ... Letai A, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm is Dependent on BCL-2 and Sensitive to Venetoclax. Cancer Discovery. PMID 27986708 DOI: 10.1158/2159-8290.Cd-16-0999 |
0.492 |
|
| 2016 |
Letai A. S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver Cancer Cell. 30: 834-835. PMID 27960083 DOI: 10.1016/J.Ccell.2016.11.016 |
0.426 |
|
| 2016 |
Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, Han GC, AlDubayan S, Amin-Mansour A, Schumacher SE, Litchfield K, Turnbull C, Gabriel S, Beroukhim R, Getz G, ... ... Letai A, et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 540: 114-118. PMID 27905446 DOI: 10.1038/Nature20596 |
0.408 |
|
| 2016 |
Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, ... ... Letai A, et al. Discovery and Biological Characterization of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. Febs Letters. PMID 27878989 DOI: 10.1002/1873-3468.12497 |
0.515 |
|
| 2016 |
Potter DS, Letai A. To Prime, or Not to Prime: That Is the Question Cold Spring Harbor Symposia On Quantitative Biology. 81: 131-140. PMID 27811212 DOI: 10.1101/Sqb.2016.81.030841 |
0.522 |
|
| 2016 |
Pham TD, Pham PQ, Li J, Letai AG, Wallace DC, Burke PJ. Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization. Scientific Reports. 6: 35907. PMID 27786282 DOI: 10.1038/Srep35907 |
0.35 |
|
| 2016 |
Bhola PD, Mar BG, Lindsley RC, Ryan JA, Hogdal LJ, Vo TT, DeAngelo DJ, Galinsky I, Ebert BL, Letai A. Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. The Journal of Clinical Investigation. PMID 27599292 DOI: 10.1172/Jci82908 |
0.81 |
|
| 2016 |
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, ... ... Letai A, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discovery. PMID 27520294 DOI: 10.1158/2159-8290.Cd-16-0313 |
0.408 |
|
| 2016 |
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Letai A, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 30: 183. PMID 27479034 DOI: 10.1016/J.Ccell.2016.06.008 |
0.445 |
|
| 2016 |
Montero J, Letai A. Dynamic BH3 profiling-poking cancer cells with a stick. Molecular and Cellular Oncology. 3. PMID 27314085 DOI: 10.1080/23723556.2015.1040144 |
0.424 |
|
| 2016 |
Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, ... ... Letai A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7: 11589. PMID 27199251 DOI: 10.1038/Ncomms11589 |
0.331 |
|
| 2016 |
Brem EA, Letai A. BOK: Oddball of the BCL-2 Family. Trends in Cell Biology. 26: 389-390. PMID 27156889 DOI: 10.1016/J.Tcb.2016.04.007 |
0.4 |
|
| 2016 |
Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, Montero J, Letai A, Russell N. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. PMID 27092880 DOI: 10.18632/Oncotarget.8742 |
0.423 |
|
| 2016 |
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Letai A, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/J.Ccell.2016.03.008 |
0.527 |
|
| 2016 |
Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, ... Letai A, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism. Blood. PMID 27069256 DOI: 10.1182/Blood-2016-01-688796 |
0.526 |
|
| 2016 |
Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy with BH3 mimetics: recent successes, current challenges and future promise. The Febs Journal. PMID 26996748 DOI: 10.1111/Febs.13714 |
0.499 |
|
| 2016 |
Bhola PD, Letai A. Mitochondria-Judges and Executioners of Cell Death Sentences. Molecular Cell. 61: 695-704. PMID 26942674 DOI: 10.1016/J.Molcel.2016.02.019 |
0.509 |
|
| 2016 |
Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biological Chemistry. 397: 671-8. PMID 26910743 DOI: 10.1515/hsz-2016-0107 |
0.405 |
|
| 2016 |
Koss B, Ryan J, Budhraja A, Szarama K, Yang X, Bathina M, Cardone MH, Nikolovska-Coleska Z, Letai A, Opferman JT. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget. PMID 26862853 DOI: 10.18632/Oncotarget.7204 |
0.479 |
|
| 2016 |
Pen JL, Laurent M, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou J, Letaï A, Braun F, Juin P. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL Cell Death and Disease. 7: 0. PMID 26844698 DOI: 10.1038/Cddis.2015.400 |
0.472 |
|
| 2016 |
Ryan J, Montero J, Rocco J, Letai A. IBH3: Simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry Biological Chemistry. 397: 671-678. DOI: 10.1515/Hsz-2016-0107 |
0.501 |
|
| 2016 |
Ariës I, Chonghaile TN, Karim S, Jacob M, Stevenson KE, Neuberg DS, Devidas M, Loh M, Hunger S, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, ... ... Letai A, et al. PRC2 mutations induce resistance to conventional chemotherapy by inhibiting mitochondrial apoptosis in T-cell acute lymphoblastic leukemia Blood. 128: 604-604. DOI: 10.1182/Blood.V128.22.604.604 |
0.496 |
|
| 2016 |
Brown FC, Still E, Cifani P, Reed C, Ficarro S, He J, Koche R, Bhola P, Romanienko P, Mark W, Krivtsov AV, Letai A, Gray N, Marto J, Armstrong SA, et al. Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia Blood. 128: 436-436. DOI: 10.1182/Blood.V128.22.436.436 |
0.424 |
|
| 2016 |
Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells Blood. 128: 4346-4346. DOI: 10.1182/Blood.V128.22.4346.4346 |
0.527 |
|
| 2016 |
Montero J, Stephansky J, Cai T, Griffin GK, Togami K, Cabal-Hierro L, LeBoeuf NR, Hogdal L, Galinsky I, Aster JC, Davids MS, Pemmaraju N, Stone RM, Konopleva M, Letai A, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax Blood. 128: 4045-4045. DOI: 10.1182/Blood.V128.22.4045.4045 |
0.327 |
|
| 2016 |
Fruman DA, Lee JS, Vo TT, Bhatt S, Schatz JH, Letai A. Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma Blood. 128: 3969-3969. DOI: 10.1182/Blood.V128.22.3969.3969 |
0.543 |
|
| 2016 |
Koch R, Brem E, Clark R, Kupper TS, Letai A, Weinstock DM. A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas Blood. 128: 292-292. DOI: 10.1182/Blood.V128.22.292.292 |
0.476 |
|
| 2016 |
Lee DJ, Rosenblat TL, Heaney ML, Jurcic JG, Raza A, Gazivoda K, Harwood K, Shelton R, Djaballah H, Scandura JM, Letai A, Frattini MG. Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies Blood. 128: 2816-2816. DOI: 10.1182/Blood.V128.22.2816.2816 |
0.383 |
|
| 2016 |
Adamia S, Nemeth J, Bhatt S, Walker SR, Voeks NI, Lento W, Attar RM, Galinsky I, Frank DA, Wadleigh M, Letai A, Steensma DP, Weinstock DM, DeAngelo DJ, Dorfman DM, et al. FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML) Blood. 128: 1681-1681. DOI: 10.1182/Blood.V128.22.1681.1681 |
0.407 |
|
| 2016 |
Zhang Q, Han L, Shi C, Pan R, MA MCJ, Ryan J, Kurtz SE, Mu H, Ruvolo V, Ma H, Andreeff M, Mi Y, Tyner JW, Leverson J, Letai A, et al. Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML Blood. 128: 101-101. DOI: 10.1182/Blood.V128.22.101.101 |
0.488 |
|
| 2016 |
Guerriero JL, Sotayo A, Ponichtera H, Pourzia A, Schad S, Carrasco R, Suzan L, Bronson R, Letai A. Abstract A40: Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A40 |
0.342 |
|
| 2016 |
Letai AG. Abstract SY43-01: Precision cancer medicine using BH3 profiling Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Sy43-01 |
0.399 |
|
| 2016 |
bhatt s, weinstock d, Letai A. Abstract 418: Mitochondrial perturbations as a novel approach to personalized medicine Cancer Research. 76: 418-418. DOI: 10.1158/1538-7445.Am2016-418 |
0.508 |
|
| 2016 |
Montero J, Sadowicz DE, Ryan J, Yoon CH, Haq R, Letai A. Abstract 3491: Rational combination of targeted agents and BH3 mimetics to improve cancer treatment Cancer Research. 76: 3491-3491. DOI: 10.1158/1538-7445.Am2016-3491 |
0.486 |
|
| 2015 |
Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, ... ... Letai A, et al. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports. 13: 2715-27. PMID 26711339 DOI: 10.1016/J.Celrep.2015.12.003 |
0.448 |
|
| 2015 |
Letai A. Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell! Clinical Cancer Research. 21: 5015-5020. PMID 26567360 DOI: 10.1158/1078-0432.Ccr-15-1204 |
0.437 |
|
| 2015 |
Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews. Cancer. PMID 26536825 DOI: 10.1038/Nrc4015 |
0.353 |
|
| 2015 |
Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, ... ... Letai A, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice. Leukemia. PMID 26202935 DOI: 10.1038/Leu.2015.194 |
0.455 |
|
| 2015 |
Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood. 126: 1555-64. PMID 26194763 DOI: 10.1182/Blood-2015-01-624585 |
0.325 |
|
| 2015 |
Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, ... ... Letai A, et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 28: 29-41. PMID 26175414 DOI: 10.1016/J.Ccell.2015.06.005 |
0.38 |
|
| 2015 |
Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. PMID 26174630 DOI: 10.1038/Leu.2015.184 |
0.324 |
|
| 2015 |
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042 |
0.653 |
|
| 2015 |
Dutta S, Ryan J, Chen TS, Kougentakis C, Letai A, Keating AE. Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. Journal of Molecular Biology. 427: 1241-53. PMID 25451027 DOI: 10.1016/J.Jmb.2014.09.030 |
0.448 |
|
| 2015 |
Rosenblat TL, Jurcic JG, Heaney ML, Raza A, Mears JG, Santos R, Carrillo D, Gonzales J, Harwood K, Santos M, Zhang R, Ibanez G, Hogdal L, Crombie JL, Djaballah H, ... ... Letai AG, et al. A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E18025 |
0.334 |
|
| 2015 |
Townsend EC, DeSouza T, Murakami MA, Montero J, Stevenson K, Christie AL, Christodolou AN, Vojinovic U, Kopp N, Barzaghi-Rinaudo P, Murakami M, Letai A, Jeay S, Wuerthner J, Halilovic E, et al. The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts Blood. 126: 797-797. DOI: 10.1182/Blood.V126.23.797.797 |
0.424 |
|
| 2015 |
Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL Blood. 126: 490-490. DOI: 10.1182/Blood.V126.23.490.490 |
0.504 |
|
| 2015 |
DiNardo C, Pollyea D, Pratz K, Thirman MJ, Letai A, Frattini M, Jonas B, Leverson J, Zhu M, Dunbar M, Falotico N, Kirby R, Agarwal S, Mabry M, Potluri J, et al. A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy Blood. 126: 327-327. DOI: 10.1182/Blood.V126.23.327.327 |
0.311 |
|
| 2015 |
Guerriero JL, Letai A. Abstract A71: Modulation of macrophages in breast tumors towards an anti-tumor phenotype Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A71 |
0.373 |
|
| 2015 |
Letai A, Hogdal L, Chonghaile T, Gutierrez A, Roderick J, Kelliher M, Konopleva M. Abstract IA29: Using mitochondria to guide leukemia therapy. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-Ia29 |
0.483 |
|
| 2015 |
Hogdal L, Chyla B, McKeegan E, Leverson J, Potluri J, Humerickhouse R, Mack M, DeAngelo D, Galinsky I, Stone R, Letai A. Abstract B10: Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B10 |
0.542 |
|
| 2015 |
Guerriero JL, Letai A. Abstract A17: Modulation of tumor-associated macrophages towards an antitumor phenotype Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A17 |
0.385 |
|
| 2015 |
Letai AG. Abstract SY20-01: Conventional chemotherapy cures people by exploiting apoptotic priming Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Sy20-01 |
0.507 |
|
| 2015 |
Sarosiek KA, Karst A, Winter P, Sorrentino A, Bandyopadhyay S, Goga A, Wood KC, Drapkin R, Letai A. Abstract 970: Broad therapy resistance is induced by suppression of apoptotic priming by lineage programs and oncogenic activation Cancer Research. 75: 970-970. DOI: 10.1158/1538-7445.Am2015-970 |
0.496 |
|
| 2015 |
Sarosiek KA, Ziller M, Fraser C, Bhola P, Ryan J, Deng J, Jian B, Goldenberg M, Madsen J, Carrasco R, Robinson S, Moslehi J, Letai A. Abstract 4728: Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity Cancer Research. 75: 4728-4728. DOI: 10.1158/1538-7445.Am2015-4728 |
0.41 |
|
| 2015 |
Ponichtera HE, Guerriero JL, Sotayo AO, Letai A. Abstract 460: Novel compound elicits anti-tumor macrophages associated with tumor regression in breast cancer Cancer Research. 75: 460-460. DOI: 10.1158/1538-7445.Am2015-460 |
0.359 |
|
| 2015 |
Hogdal L, Chyla B, McKeegan E, Leverson J, Potluri J, Falotico N, Ricker J, Humerickhouse R, Mabry M, Foight G, Keating A, Galinsky I, Stone R, DeAngelo D, Konopleva M, ... Letai A, et al. Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia Cancer Research. 75: 2834-2834. DOI: 10.1158/1538-7445.Am2015-2834 |
0.482 |
|
| 2015 |
Montero J, Sadowicz DE, Haq R, Letai A. Abstract C6: Antiapoptotic defense evolution in cancer: novel therapeutic strategies to restore cell death using dynamic BH3 profiling Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C6 |
0.514 |
|
| 2014 |
Letai A, Chonghaile TN, Hogdal LJ, Bhola PD, Montero J, Touzeau C, Ryan J. 51INTARGETING THE BCL-2 PATHWAY. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv20. PMID 28170596 DOI: 10.1093/Annonc/Mdu301.2 |
0.52 |
|
| 2014 |
Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Science Signaling. 7: ra122. PMID 25538080 DOI: 10.1126/Scisignal.2005301 |
0.428 |
|
| 2014 |
Foight GW, Ryan JA, Gullá SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. Acs Chemical Biology. 9: 1962-8. PMID 25052212 DOI: 10.1021/Cb500340W |
0.407 |
|
| 2014 |
Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, ... ... Letai A, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4520-31. PMID 25013123 DOI: 10.1158/1078-0432.Ccr-14-0259 |
0.445 |
|
| 2014 |
Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discovery. 4: 1074-87. PMID 24994123 DOI: 10.1158/2159-8290.Cd-14-0353 |
0.419 |
|
| 2014 |
Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barillé-Nion S. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death & Disease. 5: e1291. PMID 24922075 DOI: 10.1038/Cddis.2014.251 |
0.535 |
|
| 2014 |
Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, Malumbres M, Letai A, Kirschner MW, Sun Y, Wei W. APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Developmental Cell. 29: 377-91. PMID 24871945 DOI: 10.1016/J.Devcel.2014.04.022 |
0.492 |
|
| 2014 |
Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka K, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, ... Letai A, et al. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 99: 1499-508. PMID 24859877 DOI: 10.3324/Haematol.2014.104166 |
0.391 |
|
| 2014 |
Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, Letai A, Medema JP. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells Cell Death & Differentiation. 21: 1170-1177. PMID 24682005 DOI: 10.1038/Cdd.2014.37 |
0.489 |
|
| 2014 |
Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Research. 74: 3146-56. PMID 24675361 DOI: 10.1158/0008-5472.Can-13-3728 |
0.494 |
|
| 2014 |
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, ... ... Letai AG, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discovery. 4: 362-75. PMID 24346116 DOI: 10.1158/2159-8290.Cd-13-0609 |
0.522 |
|
| 2014 |
Murphy ÃC, Weyhenmeyer B, Noonan J, Kilbride SM, Schimansky S, Loh KP, Kögel D, Letai AG, Prehn JH, Murphy BM. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis : An International Journal On Programmed Cell Death. 19: 629-42. PMID 24213561 DOI: 10.1007/S10495-013-0935-2 |
0.492 |
|
| 2014 |
Rosenblat T, Heaney ML, Jurcic JG, Raza A, Mears JG, Santos R, Carrillo D, Shum D, Gonzales J, Zikaras K, Santos M, Zhang R, Ibanezs G, Hogdal L, Crombie J, ... ... Letai AG, et al. A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies Blood. 124: 974-974. DOI: 10.1182/Blood.V124.21.974.974 |
0.421 |
|
| 2014 |
Touzeau C, Ryan J, Moreau P, Chonghaile TN, Gouill SL, Richardson PG, Anderson KC, Amiot M, Letai AG. BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics Blood. 124: 417-417. DOI: 10.1182/Blood.V124.21.417.417 |
0.502 |
|
| 2014 |
Li LS, Wu S, Kopp N, Montero J, Ryan J, Chapuy B, Zwet JCVd, Layer J, Weigert O, Christie AL, Christodoulou AN, Liu H, Yoda A, Hofmann F, Baffert F, ... ... Letai AG, et al. Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs) Blood. 124: 3713-3713. DOI: 10.1182/Blood.V124.21.3713.3713 |
0.392 |
|
| 2014 |
Davids MS, Deng J, Ryan J, Fernandes SM, Brown JR, Letai AG. Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia Blood. 124: 1940-1940. DOI: 10.1182/Blood.V124.21.1940.1940 |
0.459 |
|
| 2014 |
Murase K, Kim HT, Hirakawa M, Matos TR, Kawano Y, Ryan J, Matsuoka K, Koreth J, Soiffer RJ, Letai AG, Kato J, Ritz J. Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells Blood. 124: 1414-1414. DOI: 10.1182/Blood.V124.21.1414.1414 |
0.331 |
|
| 2014 |
Konopleva M, Pollyea DA, Potluri J, Chyla BJ, Busman T, McKeegan E, Salem A, Zhu M, Ricker JL, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Leverson JD, ... ... Letai AG, et al. A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) Blood. 124: 118-118. DOI: 10.1182/Blood.V124.21.118.118 |
0.303 |
|
| 2014 |
Suryani S, Carol H, Frimantas V, Bornhauser B, Sarmah C, Chonghaile T, Evans K, Tonna E, Jones L, Letai A, Bourquin J, Houghton PJ, Smith MA, Lock RB. Abstract B26: Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B26 |
0.505 |
|
| 2014 |
Diaz-Flores E, Weng J, Akutagawa J, Holmfeldt L, Chonghaile T, Letai A, Mullighan C, Braun B, Loh M. Abstract 332: Targeting BCL-2 in hypodiploid acute lymphoblastic leukemia Cancer Research. 74: 332-332. DOI: 10.1158/1538-7445.Am2014-332 |
0.492 |
|
| 2014 |
Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, Feldser DM, Hemann MT, Letai A, Jacks T. Abstract 2961: The level of mitochondrial apoptotic priming determines cell fate upon p53 restoration Cancer Research. 74: 2961-2961. DOI: 10.1158/1538-7445.Am2014-2961 |
0.466 |
|
| 2014 |
Montero J, Sarosiek KA, DeAngelo JD, Piao H, Horowitz N, Berkowitz R, Matulonis U, Drapkin R, Letai A. Abstract 2837: Hitting the target: Dynamic BH3 profiling, a novel functional assay to predict chemotherapy response Cancer Research. 74: 2837-2837. DOI: 10.1158/1538-7445.Am2014-2837 |
0.509 |
|
| 2014 |
Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, Juin P, Barillé-Nion S. Erratum: Bcl-xL controls a switch between cell death modes during mitotic arrest Cell Death and Disease. 5. DOI: 10.1038/Cddis.2014.436 |
0.325 |
|
| 2013 |
Deng J, Letai A. Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer. Breast Cancer Research : Bcr. 15: 317. PMID 24172207 DOI: 10.1186/Bcr3568 |
0.502 |
|
| 2013 |
Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Molecular Cell. 51: 751-65. PMID 24074954 DOI: 10.1016/J.Molcel.2013.08.048 |
0.482 |
|
| 2013 |
Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends in Cell Biology. 23: 612-9. PMID 24060597 DOI: 10.1016/J.Tcb.2013.08.003 |
0.535 |
|
| 2013 |
Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agrawal V, Agarwal V, Letai A, Lerou PH, Lahav G. High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell. 13: 483-91. PMID 23954752 DOI: 10.1016/J.Stem.2013.07.018 |
0.441 |
|
| 2013 |
Montero J, Dutta C, van Bodegom D, Weinstock D, Letai A. p53 regulates a non-apoptotic death induced by ROS. Cell Death and Differentiation. 20: 1465-74. PMID 23703322 DOI: 10.1038/Cdd.2013.52 |
0.475 |
|
| 2013 |
Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leukemia & Lymphoma. 54: 1823-1825. PMID 23614795 DOI: 10.3109/10428194.2013.796051 |
0.479 |
|
| 2013 |
Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods (San Diego, Calif.). 61: 156-64. PMID 23607990 DOI: 10.1016/J.Ymeth.2013.04.006 |
0.461 |
|
| 2013 |
Hogdal LJ, Letai A. BCL-2 Inhibition: Stemming the Tide of Myeloid Malignancies Cell Stem Cell. 12: 269-270. PMID 23472867 DOI: 10.1016/J.Stem.2013.02.006 |
0.366 |
|
| 2013 |
Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 23: 139-141. PMID 23410971 DOI: 10.1016/J.Ccr.2013.01.018 |
0.401 |
|
| 2013 |
Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology. 161: 117-27. PMID 23373539 DOI: 10.1111/Bjh.12231 |
0.419 |
|
| 2013 |
Moore VDG, Letai A. BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Letters. 332: 202-205. PMID 22230093 DOI: 10.1016/J.Canlet.2011.12.021 |
0.455 |
|
| 2013 |
Murase K, Kawano Y, Ryan J, Matsuoka K, Bascug G, McDonough S, Smith RW, Cowens K, Lazo-Kallanian S, Daley J, Koreth J, Soiffer RJ, Letai A, Ritz J. Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells Blood. 122: 3475-3475. DOI: 10.1182/Blood.V122.21.3475.3475 |
0.375 |
|
| 2013 |
Akahane K, Sanda T, Mansour MR, Etchin J, Cherry N, Weinstock DM, Letai A, DeAngelo DJ, Look AT. HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase Blood. 122: 2528-2528. DOI: 10.1182/Blood.V122.21.2528.2528 |
0.447 |
|
| 2013 |
Hogdal L, DeAngelo DJ, Stone RM, Gaidzik VI, Bucci D, Döhner K, Marcucci G, Ryan J, Letai A. BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia Blood. 122: 238-238. DOI: 10.1182/Blood.V122.21.238.238 |
0.551 |
|
| 2013 |
Hernandez-Ilizaliturri FJ, Czuczman MS, Rodig S, Letai AG. Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma Blood. 122: 1764-1764. DOI: 10.1182/Blood.V122.21.1764.1764 |
0.522 |
|
| 2013 |
Patel LG, Paranal RM, Ryan J, Sarosiek K, Bradner JE, Letai A. Abstract 4610: Small molecule inhibitors of membrane-bound MCL-1 and BCL-2. Cancer Research. 73: 4610-4610. DOI: 10.1158/1538-7445.Am2013-4610 |
0.396 |
|
| 2013 |
Montero J, Letai A. Abstract 4569: Personalizing cancer therapy using dynamic BH3 profiling. Cancer Research. 73: 4569-4569. DOI: 10.1158/1538-7445.Am2013-4569 |
0.505 |
|
| 2013 |
Sarosiek KA, Bachman J, Montero J, Patel L, Sims JJ, Chi X, Andrews DW, Sorger P, Letai A. Abstract 1713: BAX and BAK are preferentially activated by BIM and BID, respectively, affecting clinical chemotherapy response. Cancer Research. 73: 1713-1713. DOI: 10.1158/1538-7445.Am2013-1713 |
0.453 |
|
| 2013 |
Montero J, Chonghaile TN, Sarosiek K, Ryan JA, Leah H, Letai AG. Abstract CN04-01: Poking cancer cells with BH3 profiling to personalize cancer therapy. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Cn04-01 |
0.466 |
|
| 2013 |
Deng J, Letai A. Abstract C17: Genome-wide siRNA screen identifies diverse signaling pathways converging at mitochondria to regulate cell death. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C17 |
0.5 |
|
| 2013 |
Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agrawal V, Letai A, Lerou PH, Lahav G. Erratum: High Mitochondrial Priming Sensitizes hESCs to DNA-Damage-Induced Apoptosis (Cell Stem Cell (2013) 13(4) (483–491) (S1934590913003639)(10.1016/j.stem.2013.07.018)) Cell Stem Cell. 13. DOI: 10.1016/J.Stem.2013.10.004 |
0.377 |
|
| 2013 |
Murase K, Kawano Y, Ryan J, Matsuoka K, Bascug G, McDonough SM, Smith R, Lazo-Kallanian S, Daley J, Koreth J, Soiffer RJ, Letai A, Ritz J. Regulation of Apoptotic Pathways in Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.082 |
0.313 |
|
| 2012 |
Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 151: 344-55. PMID 23063124 DOI: 10.1016/J.Cell.2012.08.038 |
0.781 |
|
| 2012 |
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, ... ... Letai A, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discovery. 2: 934-47. PMID 22961667 DOI: 10.1158/2159-8290.Cd-12-0103 |
0.325 |
|
| 2012 |
Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 120: 3501-9. PMID 22955911 DOI: 10.1182/Blood-2012-02-414060 |
0.518 |
|
| 2012 |
Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Research. 72: 4193-203. PMID 22689920 DOI: 10.1158/0008-5472.Can-11-4204 |
0.532 |
|
| 2012 |
Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. Journal of Clinical Oncology. 30: 3127-3135. PMID 22649144 DOI: 10.1200/Jco.2011.37.0981 |
0.476 |
|
| 2012 |
Rodriguez DA, Zamorano S, Lisbona F, Rojas-Rivera D, Urra H, Cubillos-Ruiz JR, Armisen R, Henriquez DR, Cheng EH, Letek M, Vaisar T, Irrazabal T, Gonzalez-Billault C, Letai A, Pimentel-Muiños FX, et al. BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1α. The Embo Journal. 31: 2322-35. PMID 22510886 DOI: 10.1038/Emboj.2012.84 |
0.352 |
|
| 2012 |
Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, ... Letai A, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 119: 1468-78. PMID 22096244 DOI: 10.1182/Blood-2011-07-368050 |
0.377 |
|
| 2012 |
Murase K, Kawano Y, Ryan J, Matsuoka K, Bascug G, McDonough S, Smith RW, Lazo-Kallanian S, Daley J, Davids MS, Letai AG, Ritz J. Differential Effects of TCR Stimulation and IL-2 On Apoptotic Pathways in CD4 Regulatory T Cells Compared to Conventional CD4 T Cells and CD8 T Cells Blood. 120: 3280-3280. DOI: 10.1182/Blood.V120.21.3280.3280 |
0.312 |
|
| 2012 |
Murase K, Kawano Y, Ryan J, Matsuoka K, Bascug G, McDonough S, Smith RW, Lazo-Kallanian S, Daley J, Koreth J, Soiffer RJ, Letai AG, Ritz J. Apoptotic Pathways of Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Blood. 120: 225-225. DOI: 10.1182/Blood.V120.21.225.225 |
0.35 |
|
| 2012 |
Barbone D, Cheung P, Yang T, Jablons DM, Sugarbaker DJ, Bueno R, Fennell DA, Letai AG, Broaddus CV. Abstract 5257: Manipulating the Noxa/Bim axis undermines the multicellular resistance of 3D tumor spheroids Cancer Research. 72: 5257-5257. DOI: 10.1158/1538-7445.Am2012-5257 |
0.468 |
|
| 2012 |
Qi L, Xu C, Sarosiek K, Ligon A, Rodig S, Wong K, Letai A, Shapiro GI. Abstract 2016: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibitionin vitroandin vivo Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2012-2016 |
0.362 |
|
| 2012 |
Letai A, Kutuk O, Vo T, Ryan J, Deng J, Sarosiek K, Chonghaile TN. 427 The mitochondrial basis of resistance to BCL-2 antagonists and conventional chemotherapy European Journal of Cancer. 48: 133. DOI: 10.1016/S0959-8049(12)72225-6 |
0.403 |
|
| 2011 |
Chonghaile TN, Letai A. Who put the "A" in Atg12: autophagy or apoptosis? Molecular Cell. 44: 844-845. PMID 22195958 DOI: 10.1016/J.Molcel.2011.12.007 |
0.41 |
|
| 2011 |
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, ... ... Letai A, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, N.Y.). 334: 1129-33. PMID 22033517 DOI: 10.1126/Science.1206727 |
0.811 |
|
| 2011 |
Letai A. Targeting Bcl-2 in CLL: cui bono? Blood. 118: 3453-3454. PMID 21960677 DOI: 10.1182/Blood-2011-08-370346 |
0.332 |
|
| 2011 |
Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ, Bueno R, Letai AG, Coussens LM, Fennell DA, Broaddus VC. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance Cell Death and Disease. 2. PMID 21697949 DOI: 10.1038/Cddis.2011.58 |
0.445 |
|
| 2011 |
Letai A. A new face of BCL-2 inhibition in CLL. Blood. 117: 2750-2751. PMID 21393499 DOI: 10.1182/Blood-2011-01-328658 |
0.32 |
|
| 2011 |
Davids MS, Lannutti BJ, Brown JR, Letai AG. BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells Blood. 118: 974-974. DOI: 10.1182/Blood.V118.21.974.974 |
0.47 |
|
| 2011 |
Thomenius M, Cerny J, Lena R, Chonghaile T, Walters S, Lyle S, Nath R, Muthalagu R, Lindsey K, Letai AG, Cardone M. Using BH3 Profiling As a Predictive Indicator for Myeloma Patient Response to Bortezomib, Blood. 118: 3952-3952. DOI: 10.1182/Blood.V118.21.3952.3952 |
0.537 |
|
| 2011 |
Vo TT, Stone R, DeAngelo DJ, Frattini MG, Letai AG. Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients Blood. 118: 239-239. DOI: 10.1182/Blood.V118.21.239.239 |
0.797 |
|
| 2011 |
Chonghaile TN, Sarosiek K, Ryan J, Moore VDG, Tai Y, Richardson PG, Anderson KC, Stone RM, DeAngelo DJ, Mitsiades CS, Sallan SE, Hirsch M, Silverman LB, Carrasco R, Letai AG. Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index Blood. 118: 1442-1442. DOI: 10.1182/Blood.V118.21.1442.1442 |
0.466 |
|
| 2011 |
Qi L, Xu C, Sarosiek KA, Ligon AH, Rodig SJ, Wong K, Letai AG, Shapiro GI. Abstract LB-22: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibition in vitro and in vivo Cancer Research. 72: 2016-2016. DOI: 10.1158/1538-7445.Am2011-Lb-22 |
0.498 |
|
| 2011 |
Davids MS, Lannutti BJ, Brown JR, Letai AG. 2.25 BH3 Profiling Demonstrates that CAL-101 Restores Apoptotic Priming in Stroma-Exposed Chronic Lymphocytic Leukemia Cells Clinical Lymphoma, Myeloma & Leukemia. 11. DOI: 10.1016/J.Clml.2011.09.058 |
0.391 |
|
| 2010 |
Vo T, Letai A. BH3-only proteins and their effects on cancer. Advances in Experimental Medicine and Biology. 687: 49-63. PMID 20919637 DOI: 10.1007/978-1-4419-6706-0_3 |
0.785 |
|
| 2010 |
Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proceedings of the National Academy of Sciences of the United States of America. 107: 12895-900. PMID 20615979 DOI: 10.1073/Pnas.0914878107 |
0.304 |
|
| 2010 |
Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death & Differentiation. 17: 1624-1635. PMID 20431602 DOI: 10.1038/Cdd.2010.41 |
0.501 |
|
| 2010 |
Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 115: 3304-13. PMID 20197552 DOI: 10.1182/Blood-2009-07-233304 |
0.395 |
|
| 2010 |
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, ... ... Letai A, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 463: 899-905. PMID 20164920 DOI: 10.1038/Nature08822 |
0.567 |
|
| 2010 |
Davids MS, Brown JR, Wiestner A, Letai AG. BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma Blood. 116: 692-692. DOI: 10.1182/Blood.V116.21.692.692 |
0.435 |
|
| 2010 |
Dutta C, Song F, Price B, Letai A, Weinstock DM. Abstract 1974: Nuclear BCL2 inhibits PARP1 enzymatic activity, DNA repair, and necrotic cell death Cancer Research. 70: 1974-1974. DOI: 10.1158/1538-7445.Am10-1974 |
0.474 |
|
| 2009 |
Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. The Journal of Cell Biology. 187: 429-42. PMID 19948485 DOI: 10.1083/Jcb.200904049 |
0.51 |
|
| 2009 |
Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Human Molecular Genetics. 18: 4317-28. PMID 19679562 DOI: 10.1093/Hmg/Ddp384 |
0.357 |
|
| 2009 |
Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 114: 2699-708. PMID 19652203 DOI: 10.1182/Blood-2008-12-194290 |
0.307 |
|
| 2009 |
Letai A. Hiding from ABT-737 in lymph nodes. Blood. 113: 4132-4133. PMID 19406997 DOI: 10.1182/Blood-2008-12-192831 |
0.369 |
|
| 2009 |
Letai A. Puma strikes Bax. Journal of Cell Biology. 185: 189-191. PMID 19380876 DOI: 10.1083/Jcb.200903134 |
0.356 |
|
| 2009 |
Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science. 122: 437-41. PMID 19193868 DOI: 10.1242/Jcs.031682 |
0.439 |
|
| 2009 |
Letai A. Testing the BCL-2 Family to Direct Therapy and Predict Response. Blood. 114. DOI: 10.1182/Blood.V114.22.Sci-14.Sci-14 |
0.55 |
|
| 2008 |
Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 27. PMID 19641500 DOI: 10.1038/Onc.2009.52 |
0.483 |
|
| 2008 |
Kutuk O, Letai A. Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737 Cancer Research. 68: 7985-7994. PMID 18829556 DOI: 10.1158/0008-5472.Can-08-1418 |
0.522 |
|
| 2008 |
Moore VDG, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Advances in Experimental Medicine and Biology. 615: 159-175. PMID 18437895 DOI: 10.1007/978-1-4020-6554-5_8 |
0.498 |
|
| 2008 |
Jette CA, Flanagan AM, Ryan J, Pyati UJ, Carbonneau S, Stewart RA, Langenau DM, Look AT, Letai A. BIM and other BCL-2 family proteins exhibit cross-species conservation of function between zebrafish and mammals. Cell Death and Differentiation. 15: 1063-72. PMID 18404156 DOI: 10.1038/Cdd.2008.42 |
0.379 |
|
| 2008 |
Kutuk O, Letai A. Regulation of Bcl-2 family proteins by posttranslational modifications. Current Molecular Medicine. 8: 102-118. PMID 18336291 DOI: 10.2174/156652408783769599 |
0.372 |
|
| 2008 |
Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Reviews. Cancer. 8: 121-32. PMID 18202696 DOI: 10.1038/Nrc2297 |
0.517 |
|
| 2008 |
Flanagan AM, Letai A. BH3 domains define selective inhibitory interactions with BHRF-1 and KSHV BCL-2. Cell Death and Differentiation. 15: 580-8. PMID 18084238 DOI: 10.1038/Sj.Cdd.4402292 |
0.464 |
|
| 2008 |
Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 111: 2300-9. PMID 18056841 DOI: 10.1182/Blood-2007-06-098012 |
0.541 |
|
| 2007 |
Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Research. 67: 11867-75. PMID 18089817 DOI: 10.1158/0008-5472.Can-07-1961 |
0.462 |
|
| 2007 |
Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 12: 171-85. PMID 17692808 DOI: 10.1016/J.Ccr.2007.07.001 |
0.526 |
|
| 2007 |
Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. The Journal of Clinical Investigation. 117: 112-21. PMID 17200714 DOI: 10.1172/Jci28281 |
0.557 |
|
| 2007 |
Letai A, Shipp M, Cin Pd, Takeyama K, Deng J. Detecting Apoptotic Blocks and Sensitvity to ABT-737 and Conventional Chemotherapy Via BH3 Profiling. Blood. 110: 4523-4523. DOI: 10.1182/Blood.V110.11.4523.4523 |
0.542 |
|
| 2006 |
Letai A. Restoring cancer's death sentence. Cancer Cell. 10: 343-345. PMID 17097553 DOI: 10.1016/J.Ccr.2006.10.014 |
0.442 |
|
| 2006 |
Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9: 351-65. PMID 16697956 DOI: 10.1016/J.Ccr.2006.03.027 |
0.429 |
|
| 2006 |
Goldsmith KC, Liu X, Dam V, Morgan BT, Shabbout M, Cnaan A, Letai A, Korsmeyer SJ, Hogarty MD. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma Oncogene. 25: 4525-4533. PMID 16568093 DOI: 10.1038/Sj.Onc.1209489 |
0.472 |
|
| 2006 |
Letai A. Growth Factor Withdrawal and Apoptosis: The Middle Game Molecular Cell. 21: 728-730. PMID 16543140 DOI: 10.1016/J.Molcel.2006.03.005 |
0.379 |
|
| 2005 |
Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 8: 407-19. PMID 16286248 DOI: 10.1016/J.Ccr.2005.10.013 |
0.471 |
|
| 2005 |
Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death Journal of Clinical Investigation. 115: 2648-2655. PMID 16200198 DOI: 10.1172/Jci26250 |
0.431 |
|
| 2005 |
Letai A. BCL-2: found bound and drugged! Trends in Molecular Medicine. 11: 442-444. PMID 16150641 DOI: 10.1016/J.Molmed.2005.08.007 |
0.47 |
|
| 2005 |
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435: 677-81. PMID 15902208 DOI: 10.1038/Nature03579 |
0.491 |
|
| 2005 |
Letai A, Certo M, Brown JR, Moore V. The Molecular Basis for BCL-2 Oncogene Addiction in CLL. Blood. 106: 5008-5008. DOI: 10.1182/Blood.V106.11.5008.5008 |
0.526 |
|
| 2005 |
Chauhan D, Catley L, Velankar M, Letai A, Hideshima T, Podar K, Yasui H, Mitsiades N, Mitsiades C, Tai Y, Raje N, Munshi N, Palladino MA, Anderson KC. Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. Blood. 106: 3378-3378. DOI: 10.1182/Blood.V106.11.3378.3378 |
0.449 |
|
| 2005 |
Letai A. The BCL-2 network: Mechanistic insights and therapeutic potential Drug Discovery Today: Disease Mechanisms. 2: 145-151. DOI: 10.1016/J.Ddmec.2005.05.004 |
0.431 |
|
| 2004 |
Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia Cancer Cell. 6: 241-249. PMID 15380515 DOI: 10.1016/J.Ccr.2004.07.011 |
0.508 |
|
| 2003 |
Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 426: 671-6. PMID 14668867 DOI: 10.1038/Nature02067 |
0.347 |
|
| 2003 |
Letai A. BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics Expert Opinion On Biological Therapy. 3: 293-304. PMID 12662143 DOI: 10.1517/14712598.3.2.293 |
0.467 |
|
| 2002 |
Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics Cancer Cell. 2: 183-192. PMID 12242151 DOI: 10.1016/S1535-6108(02)00127-7 |
0.391 |
|
| 1999 |
Letai A, Kuter DJ. Cancer, Coagulation, and Anticoagulation Oncologist. 4: 443-449. DOI: 10.1634/Theoncologist.4-6-443 |
0.328 |
|
| Show low-probability matches. |